Regrowth resistance in cancer: why has it been largely ignored?
In drug-sensitive malignancies, treatment failure is a complex phenomenon resulting from both drug resistance and the rapid regrowth of malignant cells in between cycles of chemotherapy. This phenomenon has been referred to as regrowth resistance, and has been identified as a common impediment to the successful treatment of many neoplastic diseases. This phenomenon has received little attention in the past. The administration of maximally tolerated individual dosages of chemotherapeutic agents, combined with the use of biological response modifiers to slow the regrowth between courses of therapy, would be an effective approach to reduce the regrowth resistance. This also could reduce the emergence of drug resistant clones.
Preisler
H D
HD
Rush Cancer Institute, Division of Hematology and Oncology, Rush Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA.
Venugopal
P
P
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D004351:Drug Resistance; D015870:Gene Expression; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009857:Oncogenes
D000970:Antineoplastic Agents; D006131:Growth Inhibitors